TITLE:
Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

CONDITION:
Diabetes Mellitus, Insulin-Dependent

INTERVENTION:
hokt3g1 (ALA-ALA)

SUMMARY:

      To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen
      administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 8 Years to 30 Years
Criteria:

        To be eligible

          -  participants will have Type 1 diabetes, diagnosed within the previous 12 months and
             established by standard American Diabetes Association criteria.

          -  All participants will have autoantibodies: either anti-GAD65, anti-ICA512, or if
             treated with insulin for less than 7 days, anti-insulin.

          -  The age range will be between 8 and 30 years; and

          -  a minimum weight of 34 kg.
      
